questionText: To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, if he will make a comparative assessment of the potential impact of using (a) Lenacapavir, (b) other long-lasting HIV prevention drugs, (c) PrEP and (d) other daily HIV prevention drugs on levels of treatment uptake by (i) rural women and girls and (ii) other marginalised communities in Africa.
answerText: Long-acting technologies could be game-changers in the global response to HIV, but only if they reach the countries and communities that need them most, including young women and girls in sub-Saharan Africa and the most vulnerable and marginalised groups ...
heading: Africa: HIV Infection